Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06708845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

US Zamto-cel Autoimmune Diseases

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2026 to Jan 2028 · Start date: Jan 2025 to Jul 2026 · Study sites: 0 to 1 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Dec 2026 to Jan 2028
    • Start date: Jan 2025 to Jul 2026
    • Study sites: 0 to 1
    • Completion date: Dec 2026 to Jul 2028
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
Trial Details
NCT Number NCT06708845
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov